|
1
|
Chen W, Zheng R, Zhang S, et al: Annual
report on status of cancer in China, 2010. Chin J Cancer Res.
26:48–58. 2014.PubMed/NCBI
|
|
2
|
Coleman RE: Clinical features of
metastatic bone disease and risk of skeletal morbidity. Clin Cancer
Res. 12:6243–6249. 2006. View Article : Google Scholar
|
|
3
|
Tsuya A, Kurata T, Tamura K, et al:
Skeletal metastases in non-small cell lung cancer: a retrospective
study. Lung Cancer. 57:229S–232S. 2007. View Article : Google Scholar
|
|
4
|
Beattie CW, Hansen NW and Thomas PA:
Steroid receptors in human lung cancer. Cancer Res. 45:4206–4214.
1985.PubMed/NCBI
|
|
5
|
Santarpia L, Koch CA and Sarlis NJ:
Hypercalcemia in cancer patients: pathobiology and management. Horm
Metab Res. 42:153–164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–55. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krawczyk P, Nicoś M, Ramlau R, et al: The
incidence of EGFR-activating mutations in bone metastases of lung
adenocarcinoma. Pathol Oncol Res. 20:107–112. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee Y, Chung JH, Kim SE, et al:
Adenosquamous carcinoma of the lung: CT, FDG PET, and
clinicopathologic findings. Clin Nucl Med. 39:107–112.
2014.PubMed/NCBI
|
|
9
|
Yuan L, Zhang J, Tan H, et al: An analysis
of 1657 inpatients with lung cancer from 2001 to 2008. Ning xia yi
ke da xue xue bao. 32:374–377. 2010.
|
|
10
|
Bae HM, Lee SH, Kim TM, et al: Prognostic
factors for non-small cell lung cancer with bone metastasis at the
time of diagnosis. Lung Cancer. 77:572–577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Jin B, Shao M, et al: Monitoring
of carcinoembryonic antigen levels is predictive of EGFR mutations
and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Tumour Biol. 35:4921–8. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi Y, Au JS, Thongprasert S, et al: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duan JC, An TT, Wu MN, et al: Correlation
between the efficacy of epidermal growth factor receptor tyrosine
kinase inhibitors and EGFR mutations in advanced squamous cell lung
cancer. Zhonghua Jie He He Hu Xi Za Zhi. 35:323–328. 2012.[(In
Chinese)]. PubMed/NCBI
|
|
14
|
Ohashi R, Takahashi K, Miura K, et al:
Prognostic factors in patients with inoperable non-small cell lung
caner - an analysis of long-term survival patients. Gan To Kagaku
Ryoho. 33:1595–1602. 2006.PubMed/NCBI
|
|
15
|
Ivanova M, Abner S, Pierce W Jr and Klinge
C: Ligand-dependent differences in estrogen receptor
beta-interacting proteins identified in lung adenocarcinoma cells
corresponds to estrogenic responses. Proteome Sci. 9:602011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Monica V, Longo M, Felice B, et al: Role
of hormone receptor expression in patients with advanced-stage lung
cancer treated with chemotherapy. Clin Lung Cancer. 13:416–423.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pietras RJ, Márquez DC, Chen HW, et al:
Estrogen and growth factor receptor interactions in human breast
and non-small cell lung cancer cells. Steroids. 70:372–381. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stabile LP, Lyker JS, Gubish CT, et al:
Combined targeting of the estrogen receptor and the epidermal
growth factor receptor in non-small cell lung cancer shows enhanced
antiproliferative effects. Cancer Res. 65:1459–1470. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang H, Liao Y, Chen G, et al: Estrogen
upregulates the IGF-1 signaling pathway in lung cancer through
estrogen receptor-β. Med Oncol. 29:2640–2648. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siegfried JM, Hershberger PA and Stabile
LP: Estrogen receptor signaling in lung cancer. Semin Oncol.
36:524–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rodriguez-Lara V, Peña-Mirabal E,
Baez-Saldaña R, et al: Estrogen receptor beta and CXCR4/CXCL12
expression: differences by sex and hormonal status in lung
adenocarcinoma. Arch Med Res. 45:158–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siegfried JM: Smoking out reproductive
hormone actions in lung cancer. Mol Cancer Res. 12:24–31. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schwartz AG, Prysak GM, Murphy V, et al:
Nuclear estrogen receptor β in lung cancer: expression and survival
differences by sex. Clin Cancer Res. 11:7280–7287. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Navaratnam S, Skliris G, Qing G, et al:
Differential role of estrogen receptor beta in early versus
metastatic non-small cell lung cancer. Horm Cancer. 3:93–100. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lixian Z: Serum estrogen levels of lung
cancer patients and estrogen receptor expression in lung cancer
tissue and its clinical pathological significance. (unpublished PhD
thesis). Fujian Medical University 2013
|
|
26
|
Kawai H, Ishii A, Washiya K, et al:
Estrogen receptor alpha and beta are prognostic factors in
non-small cell lung cancer. Clin Cancer Res. 11:5084–5089. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mauro LV, Dalurzo M, Carlini MJ, et al:
Estrogen receptor β and epidermal growth factor receptor as
early-stage prognostic biomarkers of non-small cell lung cancer.
Oncol Rep. 24:1331–1338. 2010.PubMed/NCBI
|
|
28
|
Rossi A, Chiodini P, Sun JM, et al: Six
versus fewer planned cycles of first-line platinum-based
chemotherapy for non-small-cell lung cancer: a systematic review
and meta-analysis of individual patient data. Lancet Oncol.
15:1254–1262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gallo D, De Stefano I, Grazia Prisco M, et
al: Estrogen receptor beta in cancer: an attractive target for
therapy. Curr Pharm Des. 18:2734–2757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du KQ and Jia CX: The expression of
estrogen receptor and endocrine therapy of non-small cell lung
cancer with the expression of estrogen receptor and endocrine
therapy. Acta Acad Med Xuzhou. 30:278–280. 2010.
|
|
31
|
Wang XY, Wang Y and Liu HC: Tamoxifen
lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of
ER-positive non-small cell lung cancer cells. Biomed Pharmacother.
65:525–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pesatori AC, Carugno M, Consonni D, et al:
Hormone use and risk for lung cancer: a pooled analysis from the
International Lung Cancer Consortium (ILCCO). Br J Cancer.
109:1954–1964. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ko JC, Chiu HC, Syu JJ, et al: Tamoxifen
enhances erlotinib-induced cytotoxicity through down-regulating
AKT-mediated thymidine phosphorylase expression in human
non-small-cell lung cancer cells. Biochem Pharmacol. 88:119–127.
2014. View Article : Google Scholar : PubMed/NCBI
|
